Home
Clinical Trials
Characterization of the Metab...

Characterization of the Metabolic Fate of an Oral Arginine Form

Last Updated: 2015-02-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the metabolic fate of two oral forms of L-Arginine in healthy subjects featuring metabolic syndrome related risk factors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

NCT04163783

Healthy Volunteers

COMPLETED PHASE1

A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants

NCT07127770

Healthy Adults

COMPLETED PHASE1

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

NCT06392230

Healthy Participants

COMPLETED PHASE1

Study of RPT193 in Healthy Adult Male Subjects

NCT06087978

Healthy Male Subjects

COMPLETED PHASE1

A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects

NCT02790684

Pharmacokinetics

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a randomized crossover study including 16 healthy subjects with risk factors for metabolic syndrome and 16 healthy control subjects. According a double crossover design, each subject received two oral forms of L-arginine (A and B) in random order, and participated in a exploration day on the first day of arginine administration and after one week of supplementation with this arginine form. The two weeks of arginine supplementation were separated by a washout period of 2 weeks at least.

Each exploration extended over 24 hours after administration of the first arginine dose. Blood tests were performed at 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 h after administration of the first dose. During explorations after the supplementation period, we also collected urine (0, 2, 4, 8, 12, 24 h after the first dose).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Hypertriglyceridemic Waist

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy subjects with 'hypertriglyceridemic waist'

Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.

Intervention : A form arginine and B form arginine

Group Type EXPERIMENTAL